Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. - Wikidata - wikimedia - TriplyDB

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

http://www.wikidata.org/entity/Q37495481

about

An engineering design approach to systems biology.NF-κB signalling and cell fate decisions in response to a short pulse of tumour necrosis factor.Modeling Tumor Clonal Evolution for Drug Combinations Design Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations.Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.Looking beyond the cancer cell for effective drug combinations.Cellular determinants and microenvironmental regulation of prostate cancer metastasis.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Exploiting receptor tyrosine kinase co-activation for cancer therapy.Tumor Microenvironment and Differential Responses to Therapy.A population genetics perspective on the determinants of intra-tumor heterogeneity.Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.Time-Resolved Tracking of Mutations Reveals Diverse Allele Dynamics during Escherichia coli Antimicrobial Adaptive Evolution to Single Drugs and Drug Pairs.Drug-Driven Phenotypic Convergence Supports Rational Treatment Strategies of Chronic Infections.Spatial competition constrains resistance to targeted cancer therapy.Modeling the Subclonal Evolution of Cancer Cell Populations.From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity.The perfect personalized cancer therapy: cancer vaccines against neoantigens.Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance

P2860

Q30252189-5DDA182E-9190-462E-BDA5-19678EB08AEB Q30832764-A2DCC4DE-49AB-4644-939D-1192A47B268A Q33590430-2C2FC239-40F8-46D6-9D4C-F6C04D01304D Q33682922-702E8CC7-6DE2-42C7-9659-5B7D12F47C6B Q37397222-D8D19C2A-6B86-45BF-8AF3-2D44171FE231 Q37695228-C587B6D1-C8EF-440E-ACA5-F2DDEC5E010F Q38728970-E5834F74-B6C0-4BD7-83D9-5A4BB79C8D74 Q38730590-D4F84AC0-4E8B-4BC9-93CE-C8C6752E657C Q38786707-C1C7A380-9A12-4AB5-9F36-98D0E71F7261 Q38906990-2A8E5456-1D73-4CD4-80D6-C244F92A6543 Q39141484-E879F7CC-9E2E-4B68-9D1E-5D45F020C207 Q39169154-7DC89210-3D39-4D63-B254-6D5498E1832C Q39288360-B9A9A9C9-2316-4EFE-89ED-BC3EF5684CD7 Q42248684-0AE978B7-EF35-428D-8BA6-21440ED427C2 Q47200948-4C43C10D-8942-4DD9-A0C0-624E4683201F Q47267135-77441BE6-9B7A-4A5A-A857-40C025957321 Q49541273-DD40F97A-573A-47BB-99F2-62F5043D27BC Q50351390-46DF11B0-D333-4861-BE3A-5D69D3D7B785 Q55001351-7E8EA9FB-878D-4077-A0B9-844A6DA873B5 Q58198401-CA343142-A60B-41C0-8D1B-7DE8CB09D382 Q58743052-CCD3DC8F-1AEB-4A45-96B2-8135749D264B Q58802587-3F1782F1-551F-4DBB-A976-EE43F6679CE5

P2860

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

http://www.wikidata.org/entity/Q37495481

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

@en

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

@nl

type

label

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

@en

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

@nl

prefLabel

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

@en

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

@nl

P1433

Q37495481-ECB4AA08-273C-4025-9AE7-B043466704A1

P1476

Q37495481-E913A03B-062E-40BC-8601-7AB097D7FF6B

P2093

Q37495481-3927056B-E699-4889-B4A1-DAC1CD56CBB0

Q37495481-46AB438A-6224-44B7-84DA-26DA92D111EF

Q37495481-80E96728-85FA-48F4-9726-49E5884BA39C

Q37495481-998608FE-BD21-4B4F-9EB2-C1F51634AA1B

Q37495481-9A9D7EFF-F0CA-4A3C-80B2-406BBD686A7D

Q37495481-B7DB6964-7964-4505-8251-1EBFAACABB0D

Q37495481-E8B2665C-56BC-4F75-B744-648B5CF84558

P2860

Q37495481-08CF60F5-441F-4B3F-8932-E1A69D4FFF3E

Q37495481-0ADF179A-3789-4BEA-B1B3-76E3F36059CD

Q37495481-10693106-44CA-4A39-8318-C9883D2CF2FD

Q37495481-149342BE-D959-4D6C-A96D-3212BEAE4BE5

Q37495481-1BDB9388-5787-41C3-9843-D5574AEB792E

Q37495481-353517D2-DA62-46FB-A264-F37B99447742

Q37495481-3ABE9A0D-CC0C-4034-8E9C-F6BD187E3315

Q37495481-420A971A-740E-48C5-83B0-F01D70278119

Q37495481-446A2399-B8FD-461B-8E30-1DC6EC21EC2C

Q37495481-47C384F0-470B-4062-8C96-66542F30D844

P304

Q37495481-639C319D-A726-4D43-AFAF-5E044370518C

P31

Q37495481-BD00DD0F-2E0B-4C26-A89A-8C29DF42B58F

P356

Q37495481-AB2B2C4D-91CD-48FC-B078-896910DD58A5

P407

Q37495481-7131884D-CB1C-434D-A032-F2D48AD5334E

P433

Q37495481-079E7DD3-EFB6-4156-8583-EEFC2AA95878

P478

Q37495481-AEF54E07-36DC-48B8-B3E3-2DBB9AFE91DB

P50

Q37495481-E18C82F1-8CB4-45D7-AC1E-BB6E89EE4CA7

P577

Q37495481-708C3384-F381-4BA4-A433-B476D139D204

P698

Q37495481-866DB3CD-07F9-4FF0-B8FD-1FDE1A5D1555

P932

Q37495481-FEC81B2C-0650-4A9F-8E78-24D8E72E0833

P356

J.CELL.2016.01.045

P1433

P1476

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

@en

P2093

Boyang Zhao

http://www.w3.org/2001/XMLSchema#string

Bruce Tidor

http://www.w3.org/2001/XMLSchema#string

Joseph C Sedlak

http://www.w3.org/2001/XMLSchema#string

Justin R Pritchard

http://www.w3.org/2001/XMLSchema#string

Michael T Hemann

http://www.w3.org/2001/XMLSchema#string

Pau Creixell

http://www.w3.org/2001/XMLSchema#string

Raja Srinivas

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Targeting the adaptability of heterogeneous aneuploids

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

P304

234-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELL.2016.01.045

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P50

Douglas A Lauffenburger

P577

2016-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26924578

http://www.w3.org/2001/XMLSchema#string

P932

5152932

http://www.w3.org/2001/XMLSchema#string